Shots:
- On Completion of Acquisition Allergen will have global rights to EB-001A (aesthetic) and EB-001T (therapeutic) program currently under P-II trial
- Allergen will pay an upfront payment of $195M to Bonti addition to potential commercial milestone payments
- The focus of the acquisition is EB-001- a novel botulinum neurotoxin serotype E (BoNT/E)- with rapid onset of action in 24 hours and 2 to 4-week duration effect for medical aesthetics treatment
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
